Modafinil pharmacokinetics

Donovan JL, DeVane CL, Malcolm RJ, Mojsiak J, Nora-Chiang C, Elkashef A Taylor RM (2005). Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers. Clinical Pharmacokinetics, 44, 753-65... 

Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC, Grebow PE. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999 39 30-40. 

The pharmacokinetics of modafinil are not affected, to a clinically significant extent, by volunteer age or food intake, but both the maximum plasma concentration and the elimination half-life of the drug are increased in patients with hepatic or renal impairment. It was found that peak plasma concentrations of modafinil were reached 2.3 h after a single 200 mg oral dose in healthy volunteers. Over the dose range 200 to 600 mg, the pharmacokinetics of modafinil were linear and dose dependent. Orally administered modafinil is extensively biotransformed in the liver to the inactive metabolites modafinil acid 6 (major metabolite) and modafinil sulphone 7 (minor metabolite), before being eliminated primarily in the... 

Robertson P Jr, Helhiegel ET. Clinical pharmacokinetic profile of modafinil. CUn Pharmacokinet 2003 42(2) 123-37. 

Wong YN, Wang L, Hartman L, Simcoe D, Chen Y, Laughton W, Eldon R, Markland C, Grebow P. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol 1998 38(10) 971-8. 

Hellriegel ET, Arora S, Nelson M, Robertson P Jr. Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers. J Clin Pharmacol 2002 42(4) 450-60. 

Robertson P, Hellriegel ET. Chnical pharmacokinetic profile of modafinil. Qin Pharmacokinet 2003 42 123-127. 

No pharmacokinetic interaction appears to occur between modafinil and dexamfetamine. 

In a steady-state study, 23 healthy subjeets were given modafinil 200 mg daily for 7 days, followed by 400 mg daily for 3 weeks. During the last week, 10 of the subjeets were also given dexamfetamine 20 mg daily, 7 hours after their modafinil dose. Dexamfetamine eaused no significant change in the pharmacokinetics of modafinil and fhe combination was well tolerated. In addition, the pharmacokinetics of dexamfetamine did not appear to be affected by modafinil, when compared with values reported in the literature. Similar results were found in a single dose studyNo additional precautions appear to be necessary on concurrent use. 

MoachonG,KanmacherI, ClenetM, MatLnierD. Pharmacokinetic profile of modafinil. Drugs Today (1996) 32 (Suppl 1), 23-33. 

Robertson P, Hellreigel ET, Arora S, Nelson M Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther (2002) 71, 46-56. 

The manufacturer notes that there was no pharmacokinetic interaction between sodium oxybate and modafinil, but that the possibility of a pharmacodynamic interaction was not assessed. About 80% of patients in clinical studies were also taking CNS stimulants. ... 

---